Perspective Therapeutics, Inc. filed a current report on Form 8-K on November 9, 2026, disclosing its financial results for the quarter ended September 30, 2026, along with an updated corporate presentation posted the same day.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Exchange listing: Common Stock ($0.001 par value) trades on NYSE American under the symbol CATX.
  • Press release: A press release announcing financial results and recent business highlights was furnished as Exhibit 99.1.
  • Corporate presentation: An updated corporate presentation was filed as Exhibit 99.2 on November 9, 2026.
  • Signed by: Chief Financial Officer Joel Sendek signed the filing on behalf of the registrant.
  • Not filed for liability purposes: The information under Item 2.02, including Exhibit 99.1, is furnished and "shall not be deemed to be 'filed' for purposes of Section 18" of the Exchange Act, according to the filing.

Perspective Therapeutics Reports Third-Quarter 2026 Financial Condition

Perspective Therapeutics, Inc., a Delaware-incorporated company headquartered in Seattle, Washington, submitted this current report to disclose its operating and financial results for the third quarter of fiscal 2026. The company, which is listed on NYSE American:CATX, issued a press release on November 9, 2026, covering results for the three months ended September 30, 2026, along with what the filing describes as "recent business highlights." That press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02 of the report.

Under Item 8.01, the filing notes that on the same date the company also posted an updated corporate presentation, a copy of which is attached as Exhibit 99.2 and incorporated by reference. The filing identifies Joel Sendek, Chief Financial Officer, as the authorized signatory. The company notes it is not classified as an emerging growth company under applicable SEC rules, meaning it does not qualify to use an extended transition period for new or revised financial accounting standards.

The filing makes clear that the furnished materials under Item 2.02 carry a specific liability limitation: they are not to be treated as "filed" under Section 18 of the Exchange Act, and are not to be incorporated by reference into other company filings unless a specific reference is made. The exhibits themselves, including the press release with detailed financial figures and the corporate presentation, contain the substantive financial and operational data related to the September 30, 2026 quarter, but those documents are referenced rather than reproduced within the body of this 8-K.

What Was Disclosed

Perspective Therapeutics filed an 8-K on November 9, 2026, covering third-quarter 2026 financial results through a furnished press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), both dated the same day and signed by CFO Joel Sendek.